ArticlePharmaceuticals (Basel, Switzerland)2025

A Comprehensive Analysis of Adverse Events Associated with HER2 Inhibitors Approved for Breast Cancer Using the FDA Adverse Event Report System (FAERS).

Airi Yajima et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.